








2006 ANNUAL REVIEW



## Strong Medicine

Our Prescription for Change









## To Our Owners,

I am writing to you at a time of rapid change—for Pfizer and for the global pharmaceutical industry. Since I became Chief Executive Officer last July and formed our new management team, all of our energies have been focused on improving the performance and prospects of the company—and therefore on creating value for you.



Pfizer has considerable strengths—talented, experienced and dedicated people, outstanding medicines, a promising pipeline, strong financial resources, and unmatched scale. We have a powerful foundation and legacy on which to build our future.

At the same time, both our operating environment and our industry are changing rapidly in ways that present significant new challenges to meet, as well as exciting new opportunities to seize. And, despite strong performances from many of our in-line products and a promising pipeline, recent and future losses of exclusivity on some of the most successful medicines in history will temper our revenue growth.

We are in the early stages of making the changes we must make to succeed in light of our changing business environment. We are realistic. We are determined. And we are moving with a sense of urgency. We are also committed to being open and transparent in communicating our progress to everyone with a stake in our future.

Pfizer is exceptionally well-positioned to capitalize on what may be this century's most compelling opportunity. The world's population is aging, but incomes are growing and the expectations for improved healthcare are increasing accordingly, in both the developed and the developing world. The demand for what we do—and what we can and will do in the future—will continue to grow. Despite the enormous progress society has made in preventing and treating disease, there is still a long list of unmet medical needs that lead to premature illness, disability and death.

Innovative medicines and related products and services are the world's best hope for meeting those needs in a cost-effective manner.

The good news is that, while demand for better healthcare grows, scientists are gaining more and more knowledge about how the body works, and what it needs to stay healthy. At Pfizer, we have more product candidates, more clinical trials and more research programs than at any time in our history. We have a broad set of promising new therapies in oncology, cardiovascular disease, obesity, schizophrenia, rheumatoid arthritis, HIV infection and Alzheimer's disease, among others.

All told, we have more than 175 new compounds in development, and the resources to develop them and find more. We are very optimistic that, in the years ahead, you will see Pfizer associated with the kind of medical breakthroughs that we've introduced throughout our history. Our ultimate goal is to have a larger, more diversified portfolio of uniquely valuable medicines, complemented by value-added products and services.

At the same time, we understand that our perception of what's innovative only matters if our customers share it. Governments, managed care organizations and physicians have enormous influence over patients' ability to obtain and afford our medicines and we need to work in close partnership with them, so that our innovations reach as many patients as possible.

We must also become more open to new people and innovative ideas, wherever we can find them. And it is essential that we become a more streamlined company—one that listens to its employees and customers, moves quickly, and gives its people more opportunities for growth while holding them accountable for performance.

Making these kinds of changes will take time and commitment. But we have already taken several important steps.

We appointed a new executive leadership team and we are continuing to develop the leadership we need going forward. We cut back on layers of



## wasters one. Minimize retenues to both the short and the long term.

- We will manage an extense from our server product parties, from our promising one gradiest papeline, and from a walk congress seasonal approximation.
- With Eighter's love of one has well enquested early in the over decode, we can safting artises have We can publish plante in glasse in one hour gladof delivering art new medicalines a soon beginning early in the soon decode.

2

#### successive was Establish a lower and more facilitie was been

- We will governow that covering through the anticonfluctions is mornish, and exemplatively, exemplated experiently observers, and function trades have become exemplated and proceedings.
- We will restronce a coloratestial position of his and assume account theoretic and development width, so well as extensed fractions development and temperature quarter collection.

3

recounts erose. Courte smaller, neer accountable spending miles that will collecte measurem and time on the advantages of our scale and comprise.

We will receive an organization that condition the intergretarized against
all a result company with the male and global and of a large one. We will
become force more marks, were production and story incompanie.

4

runners rous. Activity and nors meaningfully segapt with runnings, potimine, plantines and other adhibitorium to percise them with general value.

- We will be quot open to final since and inscentive approaches, and will take a more collaboration extincte in all of our excellentage with profile materia our company. We will work further to built assured ground, and factions, extension that work the controller care tree. Plans.
- We after confine and that goest effective to having confine and all once the sports and another than even in discharging afficients and participalities that the long rate of a confine and another affirmatively endomes and finally endomes are important encounter and investigations and the confine affirmatively endomes and the confine affirmatively.

5

### PRODUCTS FORD Make Place a great place to work

- We will dismand introducing with larger management have call
  associations to get brother those in their people and materials, office
  addresses a discriber of eight is their promptes and improve
  memorability and constrains.
- We will preven disagram through training to any one their alone in grow and to nonmore short personal principle and their constitutions in one ancient.



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

